New Clinical Trial in UK for refractory/relaps... - CLL Support

CLL Support

23,088 members39,651 posts

New Clinical Trial in UK for refractory/relapsed CLL, using CD19 monoclonal

Cllcanada profile image
CllcanadaTop Poster CURE Hero
2 Replies

The main aims of this clinical study are to find out the maximum dose that can be given safely to patients, the potential side effects of the drug and how they can be managed. The study will also look at what happens to Anti-CD19 (DI-B4) inside the body.

DI-B4 is a type of drug called an Anti-CD19 monoclonal antibody which is being used to stop the growth and kill cancerous immune cells by targeting the B-cell marker (CD-19) expressed on their surface. This drug has not been given to patients before.

DI-B4 is a humanised, low-fucosylated anti-CD19 Immunoglobulin (Ig) G1 monoclonal antibody with potent antibody-dependent cell-mediated cytotoxicity (ADCC) but minimal complement dependent cytotoxicity (CDC). The target antigen, CD19, is the canonical B-cell marker that is expressed on all B-cells including the malignant B-cells in NHL, CLL and acute lymphoblastic leukaemia (ALL). The CD19 antigen is therefore an attractive B-cell lineage specific target for monoclonal antibody therapy. DI-B4 is expected to act through the depletion of normal and malignant CD19 positive cells, primarily via ADCC.

Current sites...

United Kingdom

Royal Liverpool and Broadgreen University Hospital NHS Trust Not yet recruiting

Liverpool, United Kingdom, L7 8XP

Contact: Contact Person A.R.Pettitt@liverpool.ac.uk

Principal Investigator: Andrew Petitt, Dr

The Royal London Hospital Not yet recruiting

London, United Kingdom, E1 1BB

Contact: Contact Person j.gribben@qmul.ac.uk

Principal Investigator: John Gribben, Dr

The Christie NHS Foundation Trust Not yet recruiting

Manchester, United Kingdom, M20 4BX

Contact: Contact Person John.Radford@manchester.ac.uk

Principal Investigator: John Radford, Dr

University Hospital Southampton NHS Foundation Trust Not yet recruiting

Southampton, United Kingdom, S016 6YD

Contact: Andrew Davies, Dr 023 8079 6184 A.Davies@soton.ac.uk

Principal Investigator: Andrew Davies, Dr

More

clinicaltrials.gov/ct2/show...

Written by
Cllcanada profile image
Cllcanada
Top Poster CURE Hero
To view profiles and participate in discussions please or .
Read more about...
2 Replies
splashsplash profile image
splashsplash

When are these trials likely to be opening for recruitment?

Cllcanada profile image
CllcanadaTop Poster CURE Hero

Call the location and ask?

Not what you're looking for?

You may also like...

Clinical Trials of Monoclonal antibodies AZD7442 against SARS=CoV-2 (COVID19) - majority of sites in UK and USA

There are two clinical trials of monoclonal antibodies that target covid19. AstraZeneca is...

ASH 2018: Professor Peter Hillmen on the Combination of Ibrutinib and Obinutuzumab in CLL: Timing Matters

Today we start with an important abstract from the United Kingdom that may have significant...

OxPLoreD clinical trial for those with high count MBL or early stage CLL --More recruits needed

As Milla15 wrote 6 months ago "this trial which is currently recruiting for high count Monoclonal...

Moderna's mRNA Vaccine Approach

This is the best diagram I've seen so far depicting the way Moderna's mRNA 1273 vaccine is expected...

Research shows blood cancer patients generate strong T cell immunity after SARS-CoV-2 vaccination

Today, the Doherty Institute in Melbourne, Australia, released a statement about a research study...